Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation of Iressa (gefitinib) with chemotherapy vs chemotherapy alone after progression in EGFR-mutant NSCLC
jRCT1080221863Phase 3
- Sponsor
- AstraZeneca
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Gefitinib (Iressa) + chemotherapy with Placebo + chemotherapy (2 arms).
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080221863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221863.